It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The document on the WHO website linked below states that it is common procedure to release pandemic viruses into the population in order to get a jump ahead of the real pandemic, so as to fast track the vaccine for when it is needed. In Europe, some manufacturers have conducted advance studies using a so-called "mock-up" vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. According to the website, “Such advance studies can greatly expedite regulatory approval.”
Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
Originally posted by Moshpet
Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
It does not state that they release the viri out to the public Human population.
I suspect further real research would show that they infect only their lab rats (in batches) to see how the virus will spread.
Originally posted by sanchoearlyjones
reply to post by Moshpet
Taking the entire WHO article in context, it seems to be very clear what they are inferring.
They are talking about the "importance" of creating vaccines to match the flu season appropriately. They go on to discuss more, or less the loop holes of how they get new vaccines approved in different countries.
The statement You picked out is the same one I did. When put into the overall context of the article; the WHO through different vaccine drug manufacturers are indeed exposing People unknowingly to XYZ flu strains through deviant means.
In 2007, as part of preparedness for an influenza pandemic, WHO worked together with health officials, regulatory authorities, and vaccine manufacturers to explore a broad range of issues surrounding the regulatory approval of pandemic vaccines. [1] Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines. Different regulatory pathways were assessed, and precautions needed to ensure quality, safety, and effectiveness were set out in detail.
Specific regulatory procedures have been devised to expedite the approval of pandemic vaccines. In the USA, for example, fewer data are required when the manufacturer already has a licensed influenza vaccine and intends to use the same manufacturing process for its pandemic vaccine. In the European Union, the European Medicines Agency uses a rolling review procedure whereby manufacturers can submit sets of data for regulatory review as they become available, without having to wait until all data can be submitted together in a single formal application. Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
Originally posted by sanchoearlyjones
reply to post by Moshpet
In 2007, as part of preparedness for an influenza pandemic, WHO worked together with health officials, regulatory authorities, and vaccine manufacturers to explore a broad range of issues surrounding the regulatory approval of pandemic vaccines. [1] Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines. Different regulatory pathways were assessed, and precautions needed to ensure quality, safety, and effectiveness were set out in detail.
Here in the above quote, notice no mention of the 1976 screw up when the vaccine killed more than flu, but they are telling us how wonderful the vaccine is.
>>>> What was the date of this quote, before or after the screw up?
Specific regulatory procedures have been devised to expedite the approval of pandemic vaccines. In the USA, for example, fewer data are required when the manufacturer already has a licensed influenza vaccine and intends to use the same manufacturing process for its pandemic vaccine. In the European Union, the European Medicines Agency uses a rolling review procedure whereby manufacturers can submit sets of data for regulatory review as they become available, without having to wait until all data can be submitted together in a single formal application. Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
Now, like I said in context is what matters. What is a mock up vaccine? In context why would You have a mock up vaccine with the statement that it the live strain hasn't circulated recently???????????? If it hasn't circulated recently, it is in a vaccine, it is used in a context of producing, and fast tracking vaccines; it's been used on People.......without their knowledge.
that it is common procedure to release pandemic viruses into the population in order to get a jump ahead of the real pandemic
A mock-up vaccine is a vaccine that mimics the future pandemic influenza vaccine in terms of its composition, manufacturing and control. However, instead of the pandemic influenza virus strain (which is unknown before the outbreak), the mock-up vaccine contains a strain of the influenza virus that has been specifically chosen because the population is immunologically naïve to it (i.e. has never been exposed to it).
Originally posted by jtma508
reply to post by sanchoearlyjones
See, Sancho... this is exactly the problem. You make the 'factual statement' that 'more people died from the vaccine than the flu' in 1976. Check your facts, dude. There were over 16,000 flu-related deaths in the 1976 flu season and 25 linked to the vaccine although some 300 familes are making GBS claims.
Every day on ATS people are twisting and manufacturing hyperbole about this whole H1N1 situation. And the very people who are allegedly supposed to be the checks-and-balances for the MSM are behaving far more like the National Enquirer.
Originally posted by Moshpet
Ok I'm gonna have to call horse hockey on this one.
I went to the follow on article from that 'medical site' to the one at the WHO and there is nothing stating that they released such a virus out into the community.
Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
A mock-up vaccine is a vaccine that mimics the future pandemic influenza vaccine in terms of its composition, manufacturing and control. However, instead of the pandemic influenza virus strain (which is unknown before the outbreak), the mock-up vaccine contains a strain of the influenza virus that has been specifically chosen because the population is immunologically naïve to it (i.e. has never been exposed to it).
After the final vaccine is ready, decisions on who should receive the vaccine, and when they should receive it, will be made by the government in each European Union Member State.
The EMEA’s scientific committee, the Committee for Medicinal Products for Human Use (CHMP), looks at data on the methods used to make and test the mock-up vaccine, as well as the results from studies of the vaccine tested in healthy people. This information covers the immunogenicity of the vaccine (its ability to make the immune system, the body’s defence mechanism, produce antibodies against the virus strain), as well as its safety (side effects).